摘要
背景与目的:依托泊苷联合顺铂(EP)方案是否是广泛期小细胞肺癌(small cell lungcancer,SCLC)的最佳治疗方案目前仍不确定,本研究的目的是比较伊立替康联合顺铂(IP)和EP方案一线治疗广泛期SCLC的疗效和生存期。方法:在开放、两组随机、多中心、前瞻性临床研究中,符合入组条件的广泛期SCLC患者,随机接受IP或EP一线化疗,用药方案IP组:伊立替康65 mg/m^2,第1、8天,顺铂30 mg/m^2,第1、8天,21 d为1个周期,连续4个周期;EP组:VP-16为100 mg/m^2,顺铂25 mg/m^2,第1~3天,21 d为1个周期,连续4个周期。比较两组患者的疗效、生存期及不良反应。结果:2008年12月—2010年7月,共64例广泛期SCLC患者进入研究,其中IP组35例,EP组29例。IP和EP组的客观缓解率分别是66.7%和60.7%(P=0.202);无进展生存期分别是5.7和7.1个月(P=0.719);总生存期分别是未达到和12个月(P=0.591)。IP组最常见的不良反应是粒细胞减少、腹泻、消化道反应和血小板减少,发生率分别是88.2%、40%、29.4%和26.5%;EP组最常见的不良事件是粒细胞减少、消化道反应和贫血,发生率分别是80.8%、73.1%和38.5%。结论:IP和EP方案一线治疗广泛期SCLC的疗效和生存期相同,不良反应可耐受。
Background and purpose:It is unclear whether etoposide plus cisplatin(EP)regimen is the optimal chemotherapy regimen in the treatment of patients with extensive-disease(ED)small cell lung cancer (SCLC).This study was aimed to evaluate the efficacy,survival and adverse effects of irinotecan plus cisplatin(IP)and EP as the first-line therapy for ED-SCLC.Methods:In open,controlled,randomized,multicenter and prospective clinical study,meeting experimental criteria patients were randomly assigned to IP(irinotecan 65 mg/m^2 on days 1, 8 and cisplatin 30 mg/m^2 on days 1,8)or EP(etoposide 100 mg/m^2 on days 1-3 and cisplatin 25 mg/m^2 on days 1-3). Courses were repeated every 3 weeks with 4 cycles planned.The efficacy,survival and adverse effects of two therapies were compared.Results:Between Dec.2008 and Jul.2010,64 patients with ED-SCLC were enrolled(IP,n=35;EP, n=29).The objective response rates(ORR)with IP and EP were 66.7%and 60.7%,respectively(P=0.202).Median progression-free survival(PFS)for IP and EP was 5.7 and 7.1 months,respectively(P=0.719).Overall survival(OS) for IP and EP was failed to achieve and 12 months,respectively(P=0.591).The common adverse effects of IP included neutropenia(73.5%),diarrhea(40%),nausea(29.4%)and thrombocytopenia(26.5%).The common adverse effects of EP included neutropenia(73.1%),nausea(73.1%)and anemia(38.5%).Conclusion:This study showed that there is no significant difference of the efficacy and survival of IP and EP as the first-line therapy for ED-SCLC and the adverse effects are tolerant.
出处
《中国癌症杂志》
CAS
CSCD
北大核心
2011年第10期783-788,共6页
China Oncology